ATOS
- Atossa Therapeutics, Inc.
()
Overview
Company Summary
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is primarily focused on developing novel therapeutics for the treatment of breast cancer and other conditions related to breast health. The company's mission is to discover and develop innovative therapies that can improve the lives of patients.
Atossa Therapeutics takes a unique approach to address breast cancer by targeting conditions before they become cancerous, as well as advanced-stage breast cancer. The company's research and development efforts revolve around its proprietary Endoxifen technology, which is a hormone-based therapy that is believed to reduce the risk of developing breast cancer or its recurrence.
One of Atossa Therapeutics' key products under development is Oral Endoxifen, an oral form of its proprietary Endoxifen therapy. This oral medication aims to provide a non-surgical, non-toxic treatment option for patients with both early-stage and advanced-stage breast cancer. The company is currently conducting clinical trials for Oral Endoxifen to evaluate its safety and efficacy in different patient populations.
In addition to breast cancer therapeutics, Atossa Therapeutics is also involved in the development of other products and technologies related to breast health. These include the development of a topical Endoxifen, which is intended to treat breast density and reduce the risk of breast cancer, as well as a nipple aspirate fluid (NAF) collection device, which can help in the early detection of breast cancer.
Overall, Atossa Therapeutics is focused on advancing the field of breast health with its innovative therapies and technologies aimed at preventing, treating, and detecting breast cancer. Its mission is to provide patients and healthcare providers with effective and accessible solutions to improve outcomes in breast health.